---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009066"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:53:29.761876+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Virios Therapeutics granted Nasdaq exception until Oct 28, 2024 to regain $1.00 bid price compliance

## Summary
- Nasdaq Hearing Panel grants exception until October 28, 2024 to meet minimum $1.00 bid price rule.
- If not compliant by October 11, 2024, Company must pursue a reverse stock split by the deadline.
- Failure to regain compliance by October 28, 2024 will result in delisting from Nasdaq Capital Market.
- Initial deficiency notice was received November 7, 2023; prior 180-day cure period expired April 30, 2024.

## SEC filing metadata
- accession: 0001558370-24-009066
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024009066/0001558370-24-009066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024009066/viri-20240611x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009066
- JSON: https://secwatch.observer/filing/0001558370-24-009066.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.